PRO 2023

HAS THE MARKET BEEN TOO HARSH ON $ABOS?

$PRTA: Is it worth current EV of $1.B?

Access the Big Mover Report with detailed info on the biggest clinical readouts this quarter: Big Mover table

Summary:

Summary:

Summary:

Originally posted: 3/16/23; last updated 4/12/23

First posted 3/14/2023; last updated 4/3/23

WHAT WAS THE READOUT?

Summary:

Summary

SUMMARY

Intro: Hedge Fund's led us to ACET

TERN has Big-Mover readout in Q3, 2023 in NASH, and has an active, early stage pipeline in NASH, weight loss, and oncology. Our biopharma hedge fund data gave us the idea to look closer into TERN.

First posted 2/24/23; updated 4/3/23

Last week hedge funds had to report their Q4 holdings, we analyzed 35+ biotech hedge funds to see what their favorite companies are, see the companies held by the most funds in the premium article . Last week we also saw TVTX get approval for their drug Sparsentan, check out all the upcoming March PDUFA's here . Looking forward, we still have a number of data readouts and PDUFA decisions coming in February. See catalysts coming this week/month in the table below!

SUMMARY

Summary:

The ASCO-GU meeting mid Feb  kicks off this week (abstracts Monday)! Also have the PDUFA decision for TVTX  with a target date of Friday. See catalysts coming this week/month and which are Big Movers in the table below!

Originally posted 2/9/2023; last updated 3/29/23